A Case of Mycobacterium gordonae Pulmonary Disease in a Patient with Ulcerative Colitis Treated with Infliximab.
10.3904/kjm.2015.89.4.452
- Author:
Ji Sung CHOI
1
;
Jong Wook BAE
;
Sang Won LEE
;
Gyu Ho CHOI
;
Jeong Eun SHIN
;
Na Hye MYUNG
;
Jae Seuk PARK
Author Information
1. Department of Internal Medicine, Dankook University Hospital, Dankook University Medical College, Cheonan, Korea. jspark@dankook.ac.kr
- Publication Type:Case Report
- Keywords:
Mycobacterium gordonae;
Ulcerative colitis;
Infliximab;
Tumor necrosis factor-alpha
- MeSH:
Clarithromycin;
Colitis, Ulcerative*;
Ethambutol;
Gordonia Bacterium;
Humans;
Lung Diseases*;
Mycobacterium*;
Nontuberculous Mycobacteria*;
Rifampin;
Tumor Necrosis Factor-alpha;
Ulcer*;
Infliximab
- From:Korean Journal of Medicine
2015;89(4):452-456
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Tumor necrosis factor-alpha (TNF-alpha) is a key component of the host defense against mycobacterial infection. Mycobacterium gordonae (M. gordonae) is one of the least virulent mycobacteria, and is generally considered non-pathogenic if detected from a clinical specimen. Here, we report a rare case of pulmonary M. gordonae infection in a patient with ulcerative colitis who had been treated with infliximab, a TNF-alpha antagonist. M. gordonae infection was treated successfully with clarithromycin, rifampin, and ethambutol. We believe this to be the first report of M. gordonae pulmonary disease associated with TNF-alpha antagonist treatment.
